Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
For example, moderate or strong p62 immunostaining was seen in 28.5% of cancers with TMPRSS2-ERG fusion detected by FISH and in 23.1% of cancers without such rearrangements (P < 0.0001).
|
25925890 |
2015 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
There was a significant association with early PSA recurrence, which was largely limited to ERG positive cancers.
|
24789172 |
2014 |
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Molecular subtyping revealed a strikingly low prevalence of ERG cancer with increased prevalence of SPINK1 cancer (dominant focus ERG 17%, SPINK1 26%, ERG/SPINK1 52%, single ERG/SPINK1 focus 4%).
|
24722062 |
2014 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The comparison of KPNA2 expression with deletions of PTEN, 5q21, 6q15 and 3p13 in ERG-positive and -negative cancers revealed a strong link to PTEN deletions in both subgroups (P<0.0001).
|
23887301 |
2014 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PCA3 and ERG positivity in cancer foci was positively associated (P<0.01).
|
24072184 |
2014 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Although numerous studies have investigated ERG-downstream genes, such studies have not attempted to examine miRNAs, which however are emerging to be important regulators of cancer.
|
24186205 |
2014 |
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The ERG-induced mesenchymal-like signature positively correlated with TMPRSS2-ERG prostate tissues and invasive breast cancer mRNA expression datasets reflecting a general ERG-driven pattern of malignancy.
|
24504051 |
2014 |
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Within the group of patients with Gleason score (GS) 6 and 7 PCA, the signature added prognostic value beyond GS and identified patients at higher risk of cancer deaths more accurately than GS alone or in combination with ERG status.
|
24006850 |
2014 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Combining serum PSA, PCA3, and TMPRSS2:ERG in a multivariable algorithm optimized for clinical utility improved cancer prediction (AUC = 0.88; specificity = 90% at 80% sensitivity).
|
21600800 |
2013 |
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
These 10 cases consisted of benign prostate and prostate cancer; the cancer cases were either positive or negative for ERG rearrangement and/or contained PTEN deletion.
|
23994645 |
2013 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The mean staining score for those with ERG+ advanced cancer was greater than that for the ERG+ organ-confined cancer (p = 0.0209).
|
23686669 |
2013 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Further subgroup analyses revealed that associations of high LPCAT1 expression with PSA recurrence and unfavorable tumor phenotype were largely driven by ERG negative cancers (p < 0.0001) while these effects were substantially mitigated in ERG positive cancers (p = 0.0073).
|
23941784 |
2013 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Unlike the homogenous ERG staining in cancer tissues, heterogeneous SPINK1 staining was observed in the majority of the cases.
|
23348902 |
2013 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, SPINK1 expression was unrelated to tumor phenotype and biochemical recurrence in all cancers and in the subgroup of ERG negative cancers.
|
23843146 |
2013 |
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
TMPRSS2-ERG is the most common gene fusion in PCa, whereas activation of telomerase is a common feature of various malignancies.
|
22505341 |
2012 |
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We examined 100 prostate cancer patients, diagnosed by means of prostate biopsy; fluorescence in situ hybridization (FISH) was used to detect the expression of TMPRSS2, ERG, ETV1 and ETV4 in cancer tissue.
|
23244085 |
2012 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
ERG rearrangement for predicting subsequent cancer diagnosis in high-grade prostatic intraepithelial neoplasia and lymph node metastasis.
|
22696228 |
2012 |
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Ewing's sarcoma family of tumors (ESFT) refers to aggressive malignancies which frequently harbor characteristic EWS-FLI1 or EWS-ERG genomic fusions.
|
22287547 |
2012 |
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Multivariate Cox model using GS, tumour volume and ERG intensity to predict time to cancer specific death yielded a marginally significant effect for high versus low ERG protein expression (hazard ratio (HR)=0.36; 95% confidence interval (CI): 0.10-1.38; p=0.14) and a non-significant effect for GS >7 (HR=4.85; 95%CI: 0.48, 48.65; p=0.18).
|
22300588 |
2012 |
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The junction of theTMPRSS2- and ERG-derived portions of the fusion mRNA constitutes a cancer-specific target in cells containing the T/E fusion gene.
|
23052253 |
2012 |
Malignant Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
This issue of Cancer Discovery features an article that describes distinct epigenetic mechanisms that operate in TMPRSS2-ERG fusion-negative prostate cancers.
|
23148372 |
2012 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Although TMPRSS2-ERG fusion seems to be a critical event in prostate cancer, the precise functional role in cancer development and progression is still unclear.
|
22142399 |
2011 |
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
These findings were corroborated in vivo, where the control cells gave rise to discrete nodules while the TMPRSS2/ERG-expressing cells formed malignant tumors, which expressed EMT markers.
|
21747944 |
2011 |
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
ERG gene alterations were found only in prostate malignancies and not in benign prostatic tissue or bladder small cell carcinoma.
|
21499238 |
2011 |
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Fusions between TMPRSS2, encoding the transmembrane serine protease isoform 2, and ERG, encoding the v-ets erythroblastosis virus E26 oncogene homolog, are among the most common oncogenic rearrangements observed in human cancer.
|
20601956 |
2010 |